

Hospital-Treated Gram-Negative Infections Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/HEDCC04C2E14EN.html>

Date: March 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: HEDCC04C2E14EN

Abstracts

Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.

This report contains market size and forecasts of Hospital-Treated Gram-Negative Infections in Global, including the following market information:

Global Hospital-Treated Gram-Negative Infections Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hospital-Treated Gram-Negative Infections market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Klebsiella Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hospital-Treated Gram-Negative Infections include Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d'italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd and Alcon Laboratories. etc. In 2021, the global top five players have a share approximately % in terms of

revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hospital-Treated Gram-Negative Infections companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hospital-Treated Gram-Negative Infections Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Type, 2021 (%)

Klebsiella

Acinetobacter

Coli

Cepacia

Pseudomonas

Serratia

Enterobacter

Others

Global Hospital-Treated Gram-Negative Infections Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Application, 2021 (%)

Public Hospital

Private Hospital

Global Hospital-Treated Gram-Negative Infections Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hospital-Treated Gram-Negative Infections revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hospital-Treated Gram-Negative Infections revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Merck

Pfizer

AstraZeneca

Abbott

Lupin Pharmaceuticals

Istituto Iusofarmaco d'Italia

Adelco S.A

Zhejiang Yuntao Biotechnology Co., Ltd

Alcon Laboratories

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Hospital-Treated Gram-Negative Infections Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Hospital-Treated Gram-Negative Infections Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HOSPITAL-TREATED GRAM-NEGATIVE INFECTIONS OVERALL MARKET SIZE

- 2.1 Global Hospital-Treated Gram-Negative Infections Market Size: 2021 VS 2028
- 2.2 Global Hospital-Treated Gram-Negative Infections Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Hospital-Treated Gram-Negative Infections Players in Global Market
- 3.2 Top Global Hospital-Treated Gram-Negative Infections Companies Ranked by Revenue
- 3.3 Global Hospital-Treated Gram-Negative Infections Revenue by Companies
- 3.4 Top 3 and Top 5 Hospital-Treated Gram-Negative Infections Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hospital-Treated Gram-Negative Infections Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Players in Global Market
 - 3.6.1 List of Global Tier 1 Hospital-Treated Gram-Negative Infections Companies

3.6.2 List of Global Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Hospital-Treated Gram-Negative Infections Market Size Markets, 2021 & 2028

4.1.2 Klebsiella

4.1.3 Acinetobacter

4.1.4 Coli

4.1.5 Cepacia

4.1.6 Pseudomonas

4.1.7 Serratia

4.1.8 Enterobacter

4.1.9 Others

4.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts

4.2.1 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022

4.2.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028

4.2.3 By Type - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Hospital-Treated Gram-Negative Infections Market Size, 2021 & 2028

5.1.2 Public Hospital

5.1.3 Private Hospital

5.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts

5.2.1 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022

5.2.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028

5.2.3 By Application - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hospital-Treated Gram-Negative Infections Market Size, 2021 & 2028

6.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts

6.2.1 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022

6.2.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028

6.2.3 By Region - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hospital-Treated Gram-Negative Infections Revenue, 2017-2028

6.3.2 US Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.3.3 Canada Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.3.4 Mexico Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, 2017-2028

6.4.2 Germany Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.3 France Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.4 U.K. Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.5 Italy Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.6 Russia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.7 Nordic Countries Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.4.8 Benelux Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, 2017-2028

6.5.2 China Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.5.3 Japan Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.5.4 South Korea Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.5.5 Southeast Asia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.5.6 India Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hospital-Treated Gram-Negative Infections Revenue, 2017-2028

6.6.2 Brazil Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.6.3 Argentina Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, 2017-2028

6.7.2 Turkey Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.7.3 Israel Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.7.4 Saudi Arabia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

6.7.5 UAE Hospital-Treated Gram-Negative Infections Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Merck

7.1.1 Merck Corporate Summary

7.1.2 Merck Business Overview

7.1.3 Merck Hospital-Treated Gram-Negative Infections Major Product Offerings

7.1.4 Merck Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)

7.1.5 Merck Key News

7.2 Pfizer

7.2.1 Pfizer Corporate Summary

7.2.2 Pfizer Business Overview

7.2.3 Pfizer Hospital-Treated Gram-Negative Infections Major Product Offerings

7.2.4 Pfizer Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)

7.2.5 Pfizer Key News

7.3 AstraZeneca

7.3.1 AstraZeneca Corporate Summary

7.3.2 AstraZeneca Business Overview

7.3.3 AstraZeneca Hospital-Treated Gram-Negative Infections Major Product Offerings

7.3.4 AstraZeneca Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)

7.3.5 AstraZeneca Key News

7.4 Abbott

7.4.1 Abbott Corporate Summary

7.4.2 Abbott Business Overview

- 7.4.3 Abbott Hospital-Treated Gram-Negative Infections Major Product Offerings
- 7.4.4 Abbott Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
- 7.4.5 Abbott Key News
- 7.5 Lupin Pharmaceuticals
 - 7.5.1 Lupin Pharmaceuticals Corporate Summary
 - 7.5.2 Lupin Pharmaceuticals Business Overview
 - 7.5.3 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Major Product Offerings
 - 7.5.4 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
 - 7.5.5 Lupin Pharmaceuticals Key News
- 7.6 Istituto lusofarmaco d'italia
 - 7.6.1 Istituto lusofarmaco d'italia Corporate Summary
 - 7.6.2 Istituto lusofarmaco d'italia Business Overview
 - 7.6.3 Istituto lusofarmaco d'italia Hospital-Treated Gram-Negative Infections Major Product Offerings
 - 7.6.4 Istituto lusofarmaco d'italia Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
 - 7.6.5 Istituto lusofarmaco d'italia Key News
- 7.7 Adelco S.A
 - 7.7.1 Adelco S.A Corporate Summary
 - 7.7.2 Adelco S.A Business Overview
 - 7.7.3 Adelco S.A Hospital-Treated Gram-Negative Infections Major Product Offerings
 - 7.7.4 Adelco S.A Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
 - 7.7.5 Adelco S.A Key News
- 7.8 Zhejiang yuntao biotechnology co., Ltd
 - 7.8.1 Zhejiang yuntao biotechnology co., Ltd Corporate Summary
 - 7.8.2 Zhejiang yuntao biotechnology co., Ltd Business Overview
 - 7.8.3 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Major Product Offerings
 - 7.8.4 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
 - 7.8.5 Zhejiang yuntao biotechnology co., Ltd Key News
- 7.9 Alcon Laboratories
 - 7.9.1 Alcon Laboratories Corporate Summary
 - 7.9.2 Alcon Laboratories Business Overview
 - 7.9.3 Alcon Laboratories Hospital-Treated Gram-Negative Infections Major Product

Offerings

7.9.4 Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)

7.9.5 Alcon Laboratories Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hospital-Treated Gram-Negative Infections Market Opportunities & Trends in Global Market

Table 2. Hospital-Treated Gram-Negative Infections Market Drivers in Global Market

Table 3. Hospital-Treated Gram-Negative Infections Market Restraints in Global Market

Table 4. Key Players of Hospital-Treated Gram-Negative Infections in Global Market

Table 5. Top Hospital-Treated Gram-Negative Infections Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hospital-Treated Gram-Negative Infections Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hospital-Treated Gram-Negative Infections Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hospital-Treated Gram-Negative Infections Product Type

Table 9. List of Global Tier 1 Hospital-Treated Gram-Negative Infections Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hospital-Treated Gram-Negative Infections Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hospital-Treated Gram-Negative Infections Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Hospital-Treated Gram-Negative Infections Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Hospital-Treated Gram-Negative Infections Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Hospital-Treated Gram-Negative Infections

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Hospital-Treated Gram-Negative Infections

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2023-2028

Table 30. Merck Corporate Summary

Table 31. Merck Hospital-Treated Gram-Negative Infections Product Offerings

Table 32. Merck Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), (2017-2022)

Table 33. Pfizer Corporate Summary

Table 34. Pfizer Hospital-Treated Gram-Negative Infections Product Offerings

Table 35. Pfizer Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), (2017-2022)

Table 36. AstraZeneca Corporate Summary

Table 37. AstraZeneca Hospital-Treated Gram-Negative Infections Product Offerings

Table 38. AstraZeneca Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), (2017-2022)

Table 39. Abbott Corporate Summary

Table 40. Abbott Hospital-Treated Gram-Negative Infections Product Offerings

Table 41. Abbott Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn), (2017-2022)

Table 42. Lupin Pharmaceuticals Corporate Summary

Table 43. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Product Offerings

Table 44. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue

(US\$, Mn), (2017-2022)

Table 45. Istituto lusofarmaco d'italia Corporate Summary

Table 46. Istituto lusofarmaco d'italia Hospital-Treated Gram-Negative Infections
Product Offerings

Table 47. Istituto lusofarmaco d'italia Hospital-Treated Gram-Negative Infections
Revenue (US\$, Mn), (2017-2022)

Table 48. Adelco S.A Corporate Summary

Table 49. Adelco S.A Hospital-Treated Gram-Negative Infections Product Offerings

Table 50. Adelco S.A Hospital-Treated Gram-Negative Infections Revenue (US\$, Mn),
(2017-2022)

Table 51. Zhejiang yuntao biotechnology co., Ltd Corporate Summary

Table 52. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative
Infections Product Offerings

Table 53. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative
Infections Revenue (US\$, Mn), (2017-2022)

Table 54. Alcon Laboratories Corporate Summary

Table 55. Alcon Laboratories Hospital-Treated Gram-Negative Infections Product
Offerings

Table 56. Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue
(US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Hospital-Treated Gram-Negative Infections Segment by Type in 2021
- Figure 2. Hospital-Treated Gram-Negative Infections Segment by Application in 2021
- Figure 3. Global Hospital-Treated Gram-Negative Infections Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Hospital-Treated Gram-Negative Infections Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Hospital-Treated Gram-Negative Infections Revenue in 2021
- Figure 8. By Type - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
- Figure 12. US Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
- Figure 16. Germany Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

Figure 24. China Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

Figure 30. Brazil Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028

Figure 33. Turkey Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hospital-Treated Gram-Negative Infections Revenue, (US\$, Mn), 2017-2028

Figure 37. Merck Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Pfizer Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. AstraZeneca Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Abbott Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Istituto Iusofarmaco d'Italia Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Adelco S.A Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Zhejiang Yuntao Biotechnology Co., Ltd Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Hospital-Treated Gram-Negative Infections Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/HEDCC04C2E14EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HEDCC04C2E14EN.html>